多巴胺激动剂的历史。从多巴胺的生理和药理学到催乳素瘤及帕金森病的治疗——一种主观观点。 - Suppr

Suppr

超能文献

A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease - a subjective view.

作者信息

Horowski R

机构信息

NeuroBiotec GmbH, Berlin, Germany.

出版信息

J Neural Transm (Vienna). 2007 Jan;114(1):127-34. doi: 10.1007/s00702-006-0560-0. Epub 2006 Aug 10.

DOI:10.1007/s00702-006-0560-0

PMID:16897593

Abstract

摘要

相似文献

A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease - a subjective view.

J Neural Transm (Vienna). 2007 Jan;114(1):127-34. doi: 10.1007/s00702-006-0560-0. Epub 2006 Aug 10.

[Drug therapy in Parkinson's disease].

Ned Tijdschr Geneeskd. 1999 Jan 30;143(5):234-40.

Dopaminergic drugs in development for Parkinson's disease.

Adv Neurol. 2003;91:267-71.

Dopamine and eating behavior disorders in Parkinson's disease: A complex recipe.

Mov Disord. 2019 Jun;34(6):767-768. doi: 10.1002/mds.27703.

Dopamine agonists in the treatment of prolactinoma: are they still first choice?

Intern Med J. 2011 Feb;41(2):156-61. doi: 10.1111/j.1445-5994.2010.02410.x.

Should levodopa be used anymore?

Acta Neurol Belg. 2002 Dec;102(4):163-6.

Dopamine receptor agonists in the therapy of Parkinson's disease.

J Neural Transm (Vienna). 2004 Oct;111(10-11):1375-446. doi: 10.1007/s00702-003-0059-x. Epub 2003 Dec 29.

New pharmacotherapy for Parkinson's disease.

Ann Pharmacother. 1997 Oct;31(10):1205-17. doi: 10.1177/106002809703101014.

Dopamine agonists in the treatment of Parkinson's disease.

Expert Rev Neurother. 2006 Jan;6(1):81-9. doi: 10.1586/14737175.6.1.81.

DA agonists -- non-ergot derivatives: ropinirole: management of Parkinson's disease.

Mov Disord. 2002;17 Suppl 4:S98-102. doi: 10.1002/mds.5570.

引用本文的文献

Integrating Neurology and Psychiatry throughout Educational Curricula for Healthcare Professionals.

J Exp Neurol. 2020;1(4):168-172. doi: 10.33696/neurol.1.026.

Cabergoline associated with first episode mania.

Psychosomatics. 2012 Nov-Dec;53(6):595-600. doi: 10.1016/j.psym.2012.01.005. Epub 2012 May 31.

本文引用的文献

Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome.

Sleep Med. 2006 Jan;7(1):31-5. doi: 10.1016/j.sleep.2005.05.007. Epub 2005 Sep 27.

Agonism at 5-HT2B receptors is not a class effect of the ergolines.

Eur J Pharmacol. 2005 Apr 25;513(3):225-8. doi: 10.1016/j.ejphar.2005.03.010. Epub 2005 Apr 15.

Transdermal lisuride delivery in the treatment of Parkinson's disease.

J Neural Transm Suppl. 2004(68):89-95. doi: 10.1007/978-3-7091-0579-5_10.

New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance.

Mov Disord. 2004 Jun;19(6):611-3. doi: 10.1002/mds.20202.

Striatal plasticity and motor learning-importance of circadian rhythms, sleep stages and dreaming...

Parkinsonism Relat Disord. 2004 Jul;10(5):315-7. doi: 10.1016/j.parkreldis.2004.03.005.

Apomorphine in Parkinson's disease.

Trans Am Neurol Assoc. 1951;56:251-3.

Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum.

J Neural Transm (Vienna). 2003 Oct;110(10):1119-27. doi: 10.1007/s00702-003-0027-5.

EVIDENCE FOR THE EXISTENCE OF MONOAMINE NEURONS IN THE CENTRAL NERVOUS SYSTEM. IV. DISTRIBUTION OF MONOAMINE NERVE TERMINALS IN THE CENTRAL NERVOUS SYSTEM.

Acta Physiol Scand Suppl. 1965:SUPPL 247:37+.

ASCENDING SYSTEMS OF CATECHOLAMINE NEURONS FROM THE LOWER BRAIN STEM.

Acta Physiol Scand. 1964 Dec;62:485-6. doi: 10.1111/j.1748-1716.1964.tb10446.x.

EVIDENCE FOR THE EXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. I. DEMONSTRATION OF MONOAMINES IN THE CELL BODIES OF BRAIN STEM NEURONS.

Acta Physiol Scand Suppl. 1964:SUPPL 232:1-55.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease - a subjective view.

作者信息

Horowski R

机构信息

NeuroBiotec GmbH, Berlin, Germany.

出版信息

J Neural Transm (Vienna). 2007 Jan;114(1):127-34. doi: 10.1007/s00702-006-0560-0. Epub 2006 Aug 10.

DOI:10.1007/s00702-006-0560-0

PMID:16897593

Abstract

摘要

相似文献

A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease - a subjective view.

J Neural Transm (Vienna). 2007 Jan;114(1):127-34. doi: 10.1007/s00702-006-0560-0. Epub 2006 Aug 10.

[Drug therapy in Parkinson's disease].

Ned Tijdschr Geneeskd. 1999 Jan 30;143(5):234-40.

Dopaminergic drugs in development for Parkinson's disease.

Adv Neurol. 2003;91:267-71.

Dopamine and eating behavior disorders in Parkinson's disease: A complex recipe.

Mov Disord. 2019 Jun;34(6):767-768. doi: 10.1002/mds.27703.

Dopamine agonists in the treatment of prolactinoma: are they still first choice?

Intern Med J. 2011 Feb;41(2):156-61. doi: 10.1111/j.1445-5994.2010.02410.x.

Should levodopa be used anymore?

Acta Neurol Belg. 2002 Dec;102(4):163-6.

Dopamine receptor agonists in the therapy of Parkinson's disease.

J Neural Transm (Vienna). 2004 Oct;111(10-11):1375-446. doi: 10.1007/s00702-003-0059-x. Epub 2003 Dec 29.

New pharmacotherapy for Parkinson's disease.

Ann Pharmacother. 1997 Oct;31(10):1205-17. doi: 10.1177/106002809703101014.

Dopamine agonists in the treatment of Parkinson's disease.

Expert Rev Neurother. 2006 Jan;6(1):81-9. doi: 10.1586/14737175.6.1.81.

DA agonists -- non-ergot derivatives: ropinirole: management of Parkinson's disease.

Mov Disord. 2002;17 Suppl 4:S98-102. doi: 10.1002/mds.5570.

引用本文的文献

Integrating Neurology and Psychiatry throughout Educational Curricula for Healthcare Professionals.

J Exp Neurol. 2020;1(4):168-172. doi: 10.33696/neurol.1.026.

Cabergoline associated with first episode mania.

Psychosomatics. 2012 Nov-Dec;53(6):595-600. doi: 10.1016/j.psym.2012.01.005. Epub 2012 May 31.

本文引用的文献

Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome.

Sleep Med. 2006 Jan;7(1):31-5. doi: 10.1016/j.sleep.2005.05.007. Epub 2005 Sep 27.

Agonism at 5-HT2B receptors is not a class effect of the ergolines.

Eur J Pharmacol. 2005 Apr 25;513(3):225-8. doi: 10.1016/j.ejphar.2005.03.010. Epub 2005 Apr 15.

Transdermal lisuride delivery in the treatment of Parkinson's disease.

J Neural Transm Suppl. 2004(68):89-95. doi: 10.1007/978-3-7091-0579-5_10.

New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance.

Mov Disord. 2004 Jun;19(6):611-3. doi: 10.1002/mds.20202.

Striatal plasticity and motor learning-importance of circadian rhythms, sleep stages and dreaming...

Parkinsonism Relat Disord. 2004 Jul;10(5):315-7. doi: 10.1016/j.parkreldis.2004.03.005.

Apomorphine in Parkinson's disease.

Trans Am Neurol Assoc. 1951;56:251-3.

Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum.

J Neural Transm (Vienna). 2003 Oct;110(10):1119-27. doi: 10.1007/s00702-003-0027-5.

EVIDENCE FOR THE EXISTENCE OF MONOAMINE NEURONS IN THE CENTRAL NERVOUS SYSTEM. IV. DISTRIBUTION OF MONOAMINE NERVE TERMINALS IN THE CENTRAL NERVOUS SYSTEM.

Acta Physiol Scand Suppl. 1965:SUPPL 247:37+.

ASCENDING SYSTEMS OF CATECHOLAMINE NEURONS FROM THE LOWER BRAIN STEM.

Acta Physiol Scand. 1964 Dec;62:485-6. doi: 10.1111/j.1748-1716.1964.tb10446.x.

EVIDENCE FOR THE EXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. I. DEMONSTRATION OF MONOAMINES IN THE CELL BODIES OF BRAIN STEM NEURONS.

Acta Physiol Scand Suppl. 1964:SUPPL 232:1-55.